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Abstract: Objectives: Estimate tuberculosis (TB) incidence among patients receiving HAART. Compare the dynamic of 
the CD4-cell count and viral load before notification of the TB with the dynamic among patients remaining free of TB. 
Design: Prospective cohort with ascertainment of TB cases from medical records. 
Methods: The first 404 adults HIV-1 infected patients enrolled in the Senegalese antiretroviral drug access initiative were 
eligible. CD4-cell and viral load were assessed at baseline and every 6 months. Patients receiving an antituberculosis 
treatment at HAART initiation were excluded from analysis. Any TB case notified after the first month of HAART was 
considered as an incident case. Follow-up was censored at death or at the last visit before March 31, 2008. CD4-cell 
trajectories until TB notification were compared to non-TB developers within two distinct periods: from HAART 
initiation to 24 months and after. 
Results: Over 404 eligible patients, 352 were included in this analysis. Median follow-up reached 73 months and 1821 
person-years were accrued. Half of the 42 incident cases were notified before month 19 of HAART yielding to an overall 
incident rate of 2.3/100 PY [1.7-3.1]. Annual incidence decreased with duration of HAART (trend in incidence: RR=0.26, 
p<10
-4
). During the first period, CD4-cell count dynamic of most TB patients was identical to the dynamic among patients 
remaining free of TB. Most cases of the second period occurred in a context of an immunological failure. 
Conclusions: This study provides an estimate of TB incidence among patients on HAART in Senegal and supports two 
underlying mechanisms.  
INTRODUCTION 
 Tuberculosis (TB) remains the most frequent 
opportunistic infection and a leading cause of death among 
patients receiving an antiretroviral treatment (ART) in sub-
Saharan Africa, particularly during the first months of 
treatment, and is even likely to be underestimated [1]. In 
Senegal, where TB incidence reaches 270 new cases/100 000 
population/year (2006), the government has launched an 
anti-retroviral drug access initiative in 1998 (ISAARV) [2, 
3]. Among the first adult patients on HAART, the advanced 
immunodeficiency at treatment initiation, the limited 
facilities for diagnosis of opportunistic infections and 
treatment contributed to the high early mortality after 
HAART initiation. We previously showed that TB was the 
first single cause of death [4]. In sub-Saharan countries, TB 
incidence among patients on HAART is usually reported 
over the first few years of the treatment but the long 
participation time of the first patients included in the  
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Senegalese initiative provided a unique opportunity to study 
long-term TB incidence among these patients. In addition, the 
biological monitoring allowed comparing the CD4-cell count 
and viral load dynamics between patients developing a TB and 
the others in order to formulate hypothesis regarding the 
underlying mechanisms yielding to early or late TB cases. 
METHODS 
Patients Baseline Characteristics and Initial Antiretroviral 
Regimen 
 Detailed inclusion criteria in the Senegalese antiretroviral 
drug access initiative (ISAARV) and baseline characteristics 
have been previously described [4]. Patients initially 
received two nucleoside reverse transcriptase inhibitors 
combined with either a non-nucleoside reverse transcriptase 
inhibitors for 58% of them or with an unboosted protease 
inhibitor in 42% (indinavir except two patients receiving 
nelfinavir). Only 5% of the patients were non-naïve. 
Treatment is free of charge since December 2003. 
Follow-Up Procedures 
 After a pre-enrolment and the enrolment visits, patients 
were re-examined one month after HAART initiation and 
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subsequently every two months unless an adverse event 
occurred. Every two months visit, a complete clinical 
examination was performed and every six months, a 
biological evaluation, including CD4-cell count, viral load 
assessment and checking of tolerance parameters was carried 
out. Before the antiretroviral drug prescription, adherence 
was recorded by the pharmacist. 
 Every month a meeting was held with the clinical 
research assistants, the pharmacist and the social workers to 
trace the patients not showing up at a scheduled visit. After 
six months without news, the patient was considered as lost 
to follow-up. 
Data Management 
 Data were recorded from the clinicians on a weekly basis 
by two clinical research assistants. After a double-keyboard 
entry using a web-based system (Voozanoo
®
, EpiConcept, 
Paris), they were cross-checked for discordance and 
corrected before export every quarter. 
Exclusion Criteria, TB Notification and Case Definition 
 Patients under anti-TB treatment at HAART initiation 
and cases occurring during the first month of HAART were 
excluded. Therefore, only incident cases on HAART, were 
considered. TB cases could have been declared as an adverse 
event by the clinician in charge of the patient, specifying a 
M. tuberculosis infection, pulmonary or extra-pulmonary. 
Some deaths occurred without a precise diagnosis and the 
most likely cause of death was then assigned using the post-
mortem verbal autopsy procedure we previously used [4]. 
 TB cases were defined as follows: 
• Sputum smear or culture-positive pulmonary TB: 
culture M. tuberculosis + or acid-free bacilli on 
sputum smear; 
• Sputum smear-negative pulmonary TB and extra-
pulmonary TB: 
o (suggestive clinical presentation) and 
(chest X-ray or histopathological findings 
or positive Rivalta reaction on body fluid 
with predominance of lymphocyte cells) 
and (response to anti-TB treatment after 
failure of other ATB treatment). 
o post-mortem diagnosis on review of the 
clinical file completed by a verbal autopsy. 
 Patients with both pulmonary and extra-pulmonary TB 
cases were counted as pulmonary TB. Past history of TB was 
recorded during the pre-enrolment visit. 
Data Analysis 
 Data of non-TB patients were censored at date of death 
or at last visit before March 31, 2008. Data of TB patients 
were censored at date of TB notification which could be the 
date of death if TB diagnosis was done at death only. Annual 
TB incidence rate on HAART has been estimated using the 
exact person-time accrued for the specific year. 
 Dynamic of CD4 cells and viral load before TB 
notification was examined within two periods, before and 
after 24 months on HAART, and compared to non-TB 
patients. A patient with no TB identified within the first 
period who will subsequently develop a TB during the 
second period will be considered as a non-TB patient for the 
first period and therefore serve as control for that period. No 
CD4-cell counts or VL measured on the month of TB 
notification or after were used. Missing data were not 
imputed and Stata 10 was used for all the analysis (College 
Station, Texas, USA). 
Ethical Clearance 
 The protocol was approved by the Senegal national 
ethical committee and all the patients gave their written 
informed consent. 
RESULTS 
Cohort Characteristics 
 The first 404 adult patients (221 women), enrolled in 
Dakar between August 1998 and April 2002, were eligible to 
the study. At inclusion, 55% of them were at CDC stage C 
with a median CD4-cell count of 128 [IQR 54 – 217] and a 
median viral load (VL) of 5.2 log10 [IQR: 4.7 - 5.6]. 
Cotrimoxazole prophylaxis coverage reached 78% and 28% 
of the patients had a history of TB. 
 After exclusion of 47 “prevalent” cases and five cases 
which occurred during the first month, 352 patients were 
included in the TB incidence study and followed for a 
median duration of 73 months [IQR: 28-84] (Fig. 1). As of 
March 31, 2008, the largest participation time on HAART 
reached 9.5 years and 1821 person-years of observation were 
accrued. Between two and seven patients were lost to follow-
up per year until the sixth year of the study and 91 all-cause 
deaths were recorded with a median survival time of 24 
months [IQR: 6-32]. 
TB Cases and Incidence Rate 
 At the date of analysis, 42 incident cases were identified 
among the 352 patients included in the analysis (12%) with a 
median notification time of 20 months [IQR: 7 – 51]. 
Thirteen cases were defined as sputum smear-positive 
pulmonary TB (31%), 29 as smear-negative of which seven 
were post-mortem diagnosis (24% of smear-negative). 
Thirty-four cases were pulmonary TB (81%) and eight extra-
pulmonary TB. Nineteen TB patients died (45%), of which 
12 (63%) were attributed to TB. 
 Between initiation of HAART and 24 months (first 
period), 25 cases were identified and 17 cases after 24 
months. The overall incidence rate reached 2.3 cases/100 
person-years (P-Y) [95% IC: 1.7 – 3.1]. Over the first 4 
years on HAART, the annual incidence rate decreased 
regularly from 4.5 cases/100 P-Y [95% IC: 2.8 - 7.7] during 
the first year to 3.5 [1.9 – 6.5] the second year, 1.5 [0.6 - 4.1] 
the third year and to 0.4/100 P-Y [95% IC: 0.0 – 2.9] the 
fourth year. After the fourth year, the incidence fluctuated 
with large confidence intervals around an average rate of 
1.8/100 P-Y [95% IC: 0.8-2.9]). The overall test for trend 
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showed that incidence rate decreased from year to year by ? 
on the average (RR=0.26, p<10
-4
). 
CD4-Cell and Viral Load Dynamics 
First Period (0-24 Months on HAART) 
 The main difference laid in the distribution of CD4-cell 
counts: 40% of the future TB patients were severely 
immunodepressed, as defined by a CD4 count less than 50 
cells/?L, at HAART initiation vs 22% of the TB-free patients 
(Table 1). However, the difference in median CD4-cell 
counts did not reach statistical significance. Anaemia at 
baseline was also statistically more frequent among future 
TB patients. There was no difference at HAART initiation 
between the two groups of patients with respect to gender, 
age, body mass index, cotrimoxazole prophylaxis, viral load 
or protease inhibitor-containing regimen. 
 Among the 25 cases identified within the first period, 
only 11 CD4 trajectories with at least 2 measures before TB 
notification were available. The background of Fig. (2) 
displays the 5
th
, 25
th
, 50
th
, 75
th
 and 95
th
 percentile of the 
CD4-cell progression among patients remaining free of TB 
over the period and is used as “reference” progression 
(median 24-month gain : 197 CD4-cells/?L). The 11 CD4 
trajectories of TB cases, superimposed on that background, 
shows that only three trajectories are sharply decreasing, 
crossing several quintile distribution bands between baseline 
and 6-month measurement. The other eight courses, all with 
duration before TB notification beyond six months of 
HAART, are increasing or comprised within the “reference” 
progression bands with a median gain of 124 CD4-cells/?L 
[IQR: 65 – 192] before TB notification. 
Table 1. Characteristics of the Patients at HAART Initiation 
 
Variable TB  
(n = 25) 
Non TB  
(n = 327) 
Test* 
Sexe M 14 (56%) 144 (44%) 0.3 
Age median [IQR] 37 [32 - 42] 38 [30 - 43] 0.9 
BMI < 19 kg. m-2 12 (48%) 111 (35%) 0.2 
Cotrimoxazole  
prophylaxis 
22 (88%) 265 (81%) 0.6 
Hb < 10g/dL 13 (52%) 101 (31%) 0.04 
CD4 
median [IQR] 
< 50 
50-199 
200+ 
 
95 [33 - 241] 
10 (40%) 
5 (20%) 
10 (40%) 
 
134 [60 - 218] † 
70 (22%) 
150 (47%) 
101 (31%) 
0.8 
 
0.02 
log10 VL median [IQR] 5.32 [4.75 - 5.59]
 ‡ 5.17 [4.65 - 5.53] ¥ 0.6 
Protease-based  
regimen (indinavir) 
12 (48%) 151 (46%) 0.9 
*Fisher’s exact test or non parametric median test. 
†321 measures; ‡21 measures; ¥266 measures. 
 
 
Fig. (1). Flowchart of patients selection, ANRS 1215 cohort, Senegal, 1998-2008. 
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 VL measurements were available for 21 TB cases but, as 
for the CD4-cell counts, only the baseline VL measurement 
was available for nine patients and therefore 12 VL 
trajectories before TB notification could be examined. One 
TB patient had his viral load increasing, the one with the 
largest CD4-cell diminution (VL = +1.8 log10 cp/mL; CD4 
count = - 398 cells/?L). After exclusion of that patient and, 
although non-TB and TB patients cannot be compared due to 
different follow-up durations, the median VL suppression 
did no differ between the two groups of patients 
(respectively, -2.73 log10, 266 measures vs -2.75, 11 
measures). 
Second Period (24 Months and Beyond on HAART) 
 Among the 327 patients who entered the first period and 
did not declare a TB, 48 died before 24 months, 16 were lost 
to follow-up, 263 entered the second period and 17 will 
develop a TB (Fig. 1). Examination of VL at month-24 of 
HAART, or at the first available measure in the period, 
showed that the proportion of undetectable VL was 
statistically lower among future TB patients of this period 
compared to the other patients (Table 2). The median VL 
was also statistically larger among future TB patients. 
However, the two groups of patients started the period with 
an equivalent CD4-cell level. None of the other recorded 
characteristics differed between the two groups. 
 As for the first period, CD4 cell count evolution of TB 
patients were drawn against the distribution of CD4-cell 
progression of non-TB cases (Fig. 3). Among the 17 TB 
cases identified within this period, 14 CD4 courses with at 
least 2 measures were available. For the three other patients, 
only one CD4-cell count was available before TB 
notification at 24 months (868 cells/?L) or 30 months (203, 
743 cells/?L). Among the remaining 14 patients, only four 
positive progressions with a modest increase, comprised 
 
Last CD4-cell count among TB cases (n, range, median [IQR]): 
Month M0 M6 M12 M18 
n 14 6 2 3 
range 1-322 6-287 107-461 186-486 
 
Fig. (2). First period: from HAART initiation to 24 months. CD4-cell count trajectories before TB notification (solid lines: positive gain; 
dashed lines: negative gain) and CD4-cell count progression among TB-free patients as background (solid lines from bottom to top: 5
th
, 25
th
, 
median, 75
th
 and 95
th
 percentile of the distribution). 
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within the interquartile band of CD4-cell reconstitution of 
non-TB patients, were recorded (median increase in CD4-
cell count: +32 [IQR: 15; +141]). The 10 other patients 
showed a strong deterioration of their immune status before 
TB notification (median loss in CD4-cell count: -163 [IQR: -
354; -93]) which can be seen graphically (Fig. 2). The last 
CD4 cell count exceeded 500 cells/?L among three patients 
only (868, 743, 550 cells/?L). On the average, VL did not 
increase between month-24 on HAART and TB notification 
(median VL variation = 0 [IQR: -3.3; +1.2]. The VL until 
their last visit was also stable among non-TB patients 
(median VL variation = 0 [IQR: -0.2; +0.6]. 
DISCUSSION 
 This study revealed a significant and decreasing trend in 
TB incidence among patients on HAART from 4.5 TB 
cases/100 P-Y during the first year of the treatment to 0.4 
TB/100 P-Y the fourth year. Subsequently, incidence 
fluctuated largely around 1.8 cases/100 P-Y due to the small 
number of cases and persons at risk. The examination of 
CD4-cell count dynamics before identification of TB cases 
compared to non TB cases suggested two underlying 
mechanisms, for early and late cases. 
 Given the high frequency of sputum smear-negative 
pulmonary TB in advanced immunodeficient HIV patients, 
the limited access to mycobacterial culture in the context of 
our study, and more generally in resource-limited countries, 
atypical chest X-ray images, unspecific symptoms, our 
estimates need to be taken with caution [5-7]. Less than a 
third of the incident cases were sputum smear- or culture-
positives (13/42) and 60% (24/42) were diagnosed on 
clinical or radiological criteria only. An algorithm approach 
to improve the diagnosis of smear-negative pulmonary and 
extrapulmonary TB, such as recommended in 2006 by 
WHO, was not yet implemented [8]. In addition, seven 
diagnoses were made only by post-mortem verbal autopsy 
and review of the clinical file. This lack of accuracy in TB 
diagnosis may have led to false negative as well as false 
positive cases. However, no change with time in diagnosis 
facilities happened, preventing a change in misclassification 
rate with time. 
 Despite these limitations, our estimates fit with reported 
TB incidence rates on HAART. Indeed, we have shown that 
incidence rate is rapidly falling after HAART initiation. This 
decreasing pattern is universally reported in resource-limited 
countries [9-15]. Fig. (4) summarizes published estimates as 
a function of the median duration on HAART. Our yearly 
estimates, as well as our average estimate rate of 2.3 
cases/100 P-Y over a median follow-up duration on HAART 
of 73 months, fit within this graph. A different picture 
emerges from a pooled analysis of cohorts from developed 
countries where TB incidence rate is much lower after three 
years of HAART: 0.47 case/100 P-Y [16]. The 
epidemiological setting with a lower TB prevalence in the 
general population, better TB diagnosis tools and an earlier 
access to HAART (median baseline CD4-cell count: 280 
cells/?L) are likely to explain this difference. 
 The examination of the immunovirological dynamics 
before TB notification yields to different hypothesis 
regarding the underlying mechanisms. 
 During the early period on HAART, we hypothesis that 
there was a mixture of mechanisms among the 25 ART-
associated TB cases: i) some clinical cases left undiagnosed 
at HAART initiation due to the lack of sensitive diagnosis 
tests with a persistent immunodeficiency and ii) subclinical 
latent cases at HAART initiation with a subsequent immune 
restoration within the range of the immune restoration of 
patients remaining free of TB of the same follow-up on 
HAART, “unmasking” the TB [17-20]. In a context of 
higher TB incidence, a third of the early cases was attributed 
to “unmaking” TB [15]. 
 
Table 2. Characteristics of the Patients at 24 Months on HAART 
 
Variable TB (n = 17) Non TB (n = 246) Test* 
Sex M 10 (59%) 108 (43%) 0.3 
Age median [IQR] 38 [31 - 42] 38 [31 - 44] 0.6 
BMI < 19 kg. m-2 2 (18%) 32 (17%) 0.9 
Cotrimoxazole prophylaxis 9 (53%) 95 (39%) 0.3 
Hb < 10g/dL 3 (18%) 20 (8%) 0.2 
CD4 median [IQR] 
M24 measure 
1st measure available in the period 
 
303 [241 - 568]¶ 
332 [256 – 587] 
 
347 [239 - 481]† 
360 [239 – 521] 
 
0.7 
0.8 
log10 VL median [IQR] 
M24 measure 
1st measure available 
 
2.4 [1.7 – 4.1]‡ 
2.1 [1.7 – 4.6] 
 
1.7 [1.7 – 2.9]¥ 
1.7 [1.7 – 3.0] 
 
0.02 
0.01 
Undetectable VL 
M24 measure 
1st measure available 
 
3 (25%)‡ 
4 (23%) 
 
96 (59%)¥ 
142 (58%) 
 
0.03 
0.009 
Protease-based regimen (indinavir) 6 (35%) 87 (35%) 1.0 
*Fisher’s exact test or non parametric median test 
¶11 measures; †149 measures; ‡12 measures; ¥163 measures. 
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Last CD4-cell count among TB cases (n, range, median [IQR]): 
 
Month M24 M30 M36 M42 M48 M54 M60 M66 M72 M84 
n 1 3 1 2 3 2 1 1 2 1 
value 
or 
range 
868 203 
- 
743 
332  74 - 
375 
126 
- 
428 
182 
- 
313 
129 4 220 
- 
550 
149 
 
Fig. (3). Second period: 24 months and beyond. CD4-cell count trajectories before TB notification (same as Fig. 2). 
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South Africa [10] 
Ivory Coast [11] 
Kenya [12] 
Malawi [12] 
Cameroon [12] 
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Thailand [12] 
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ART-LINC 
ART-LINC 
ART-LINC [14] 
South Africa [15] 
 
Fig. (4). Published estimates of TB incidence on HAART by median follow-up duration. 
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 However, the small number of serial CD4-cell count 
measures during the first year in TB cases precludes 
distinguishing clearly between mechanisms. Indeed, the 
constraints in TB diagnosis and biological monitoring in 
esource-limited settings, the mixture of clinical presentation, 
the heterogeneity in underlying mechanisms and the 
difficulty to differentiate between these led to propose 
grouping together all TB cases occurring after HAART 
initiation under the term “ART-associated tuberculosis” [21]. 
 Over the second period, after 24 months on HAART, the 
underlying predominant mechanism was very different. The 
notification of an incident TB case was almost always 
preceded by a fall in CD4-cell counts or a small increase, 
contrasting with a continuing gain in the CD4-cell level 
among patients remaining free of TB. In addition, a few 
patients had a persistent immunodeficiency with a CD4-cell 
count persistently below 200 cells/?L during that period. In 
South Africa, Lawn et al. showed that a low updated CD4 
cell count is associated with TB incidence, even years after 
HAART initiation and that reaching a CD4 threshold of 500 
cells/?L is necessary to minimize TB incidence rate [15]. At 
the start of this period, future TB patients did not differ from 
the other patients by their CD4-cell level but their median 
VL was 10 times greater and 75% of them had a detectable 
VL compared to 40% in the other patients. These late 
incident TB cases can be related to a virological failure, 
followed by an immunological failure, due either a lack of 
adherence, known to decrease with the duration of HAART 
in this setting, or the selection of resistance strains without 
treatment switch [22]. In other words, patients with a 
detectable VL at 24 months on HAART, even with a good 
immune restoration, were at risk of developing a TB. For the 
few TB cases with a last CD4-cells count above 500 
cells/?L, an explanation could be a suboptimal restoration of 
Mycobacterium tuberculosis-specific immune responses and 
the absence of a protective CD4-cell threshold [23, 24]. 
 This study shows that a low baseline CD4-cell count was 
associated with the occurrence of a TB within the first 2 
years on HAART. This effect has already been shown in 
Cape Town with a median follow-up of 40 months over an 
equivalent population size but not in Abidjan, perhaps due to 
a lack of power [11, 25]. Over the second period, only the 
baseline 24-month VL differed between the two groups of 
patients, highlighting again the time-dependence of risk 
factors for clinical events on HAART with 
immunodeficiency level predicting the early events and VL 
predicting later events in the course of the follow-up [26]. 
This underlines the limited access to VL testing and 
genotyping in resource-limited countries to monitor patients 
on HAART for several years in order to guide the treatment 
switch before the occurrence of clinical events. 
 The high TB incidence on HAART raises the issue of TB 
screening in all patients at HAART initiation and the 
isoniazid prevention therapy (IPT) to prevent incident cases 
[27]. Recommended by WHO in HIV-positive persons with 
strict programme prerequisites, this policy is seldom 
implemented in current management of the HIV-TB 
coinfection [28, 29]. In Brazil and South Africa in a much 
higher incidence setting, Golub et al., comparing TB 
incidence rates between cohorts receiving HAART or not 
and IPT or not, showed that IPT can reduce the risk of TB 
beyond the reduction due to HAART and call for a wider use 
of IPT combined with HAART [30, 31]. Combined with a 
screening for TB at baseline and during follow-up of the 
patient on HAART, especially during the first years, 
simulation studies shown that this recommendation could 
greatly reduce TB incidence in high incidence settings, such 
as South Africa [32]. Recently, the International Union 
Against Tuberculosis and Lung Diseases and WHO urged 
for implementing preventive intervention, including IPT 
[33]. However, given the shortcomings to exclude 
subclinical TB at baseline and the early high TB incidence 
on HAART, IPT could be delayed up to a few months on 
HAART. 
CONCLUSION 
 This study provides long-term estimates of TB incidence 
on HAART in a sub-Saharan country and confirms that the 
first months on HAART place the patients at a high risk of 
developing a TB. It suggests two main mechanisms 
depending on the duration of HAART, underlying the 
importance of improving TB screening in the short-term and 
VL monitoring in the long-term monitoring of patients. The 
issue of IPT needs to be evaluated with respect to both 
incidence rates and diagnosis facilities. 
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